Merck KGaA leads team to sell Erbitux in Japan
Call it a trifecta: ImClone Systems, Bristol-Myers Squibb and Merck KGaA are joining together to develop and market ImClone's cancer drug Erbitux in Japan, with Merck getting half the proceeds. Report [1]